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Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare autosomal recessive disorder caused by
mutations in the autoimmune regulator gene (AIRE). Terminal 4q deletion is also a rare cytogenetic abnormality that causes a
variable syndrome of dysmorphic features, mental retardation, growth retardation, and heart and limb defects. We report a 12-
year-old Saudi boy with mucocutaneous candidiasis, hypoparathyroidism, and adrenocortical failure consistent with APECED.
In addition, he has dysmorphic facial features, growth retardation, and severe global developmental delay. Patient had late
developmentofchronicrenalfailure.Theblastogenesisrevealeddepressedlymphocytes’responsetoCandidaalbicansat38%when
comparedtocontrol.Chromosomeanalysisofthepatientrevealed46,XY,del(4)(q33).FISHusinga4p/4qsubtelomereDNAprobe
assay conﬁrmed the deletion of qter subtelomere on chromosome 4. Parental chromosomes were normal. The deleted array was
further deﬁned using array CGH. AIRE full gene sequencing revealed a homozygous mutation namely 845 846insC. Renal biopsy
revealed chronic interstitial nephritis with advanced ﬁbrosis. In addition, there was mesangial deposition of C3, C1q, and IgM.
This is, to the best of our knowledge, the ﬁrst paper showing evidence of autoimmune nephropathy by renal immunoﬂuorescence
in a patient with APECED and terminal 4q deletion.
1.Introduction
AIRE gene was cloned in 1997 by two independent
groups [1, 2]. Mutations in the AIRE cause autoim-
mune polyendocrinopathy-candidiasis-ectodermal dystro-
phy (APECED, OMIM no. 240300), also known as autoim-
munepolyglandularsyndrome type1.APECED is diagnosed
based on the presence of two of a triad: hypoparathyroidism,
adrenocortical failure, and chronic mucocutaneous candidi-
asis [3, 4]. APECED has a high prevalence among Finns
(1/25000), Sardinians (1/14000), and Iranian Jews (1/8000).
Several other disorders are part of APECED like pernicious
anemia, vitiligo, thyropathy, gonadal failure, diabetes melli-
tus, and autoimmune hepatitis [4–6]. There are also reports2 Clinical and Developmental Immunology
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Figure 1: Photograph of the patient showing subtle dysmorphic features with high forehead, ﬂat facies, large protruding ears, and large
mouth, at the age of 7 years (a) and at the age of 9 years (b). Fungal infection (Candida albicans) of the nails (thumb and middle ﬁnger) and
dorsum of the hand (c) and around the mouth corners (d).
of chronic interstitial nephritis in patients with APECED
[7, 8]. AIRE clearly plays a crucial role in preventing
organ-speciﬁc autoimmunity. It regulates the expression of
ectopic proteins expressed by medullary thymic epithelial
cells which contribute signiﬁcantly to central tolerance; thus
preventingautoimmunityandproductionofautoantibodies,
and elucidating the signiﬁcant autoimmune manifestations
in APECED and AIRE−/− mice [5, 9, 10].
The terminal deletion of 4q results in a recognizable
syndrome. The deletion 4q33 has been described in 15
patients; most of these cases presented with craniofacial
anomalies, mental retardation, poor growth, and variable
heart and limb defects [11–15]. It seems that severity of the
phenotype correlates with the size of the deletion ranging
from mild physical signs in 4q34 deletion to more severe
phenotype in deletion involving 4q31 [12, 15–20]. It appears
that 4q33 is the critical region of the 4q terminal deletion
syndrome [19]. Renal disease in the form of absorptive
hypercalciuria and kidney calciﬁcation has been reported in
few children with terminal 4q deletion [13, 21].
Herein, we describe a patient with terminal deletion of
4q and features consistent with APECED. In addition, he
developed autoimmune renal involvement leading to renal
failure.
2. Patient andDiagnosis
The study was approved by the Research Advisory Council at
King Faisal Specialist Hospital and Research Centre, Riyadh,
Saudi Arabia (RAC no. 2040042). Written informed consent
was given by the parents.
2.1. Patient Report. The patient is a 12-year-old Saudi boy
(Figure 1) who was brought initially to medical care at
the age of 6 months because of delayed developmental
milestones. Both parents are reported to be healthy. They are
consanguineous (1st cousins). They have 5 other children,
4 girls and 1 boy, who are all reported to be healthy. The
patient was born at term to a 38-year-old mother and a
39-year-old father following an uncomplicated pregnancy.
At 18 months of age, the patient was noted to have oral
lesions and nail dystrophy (Figures 1(c) and 1(d)). Cultures
grew Candida albicans. His medical history was negative
for recurrent chest infections, skin abscesses, or chronic
diarrhea. Nitro Blue Tetrazolium (NBT), leukocytic markers,
and immunoglobulin levels were normal. HIV test was
negative. The blastogenesis revealed depressed lymphocytes’
response to candida at 38% when compared to control.
Nonetheless, it gave a robust response to mitogens and otherClinical and Developmental Immunology 3
(a) (b)
(c) (d) (e)
(f) (g)
Figure 2: Superﬁcial esophageal mucosa ((a),(b)) invaded by candidal psudohyphae. Grocott-Methenamine silver (original magniﬁcation
200x (a)/400x (b)). Renal biopsy ((c), (d), (e)) shows ischemic glomerular tuft with thick and wrinkled basement membrane (PAS stain
40x) (c) and extensive tubular loss with replacement by ﬁbrosis (Masson trichrome stain 40x) (d). The interstitium shows lymphocytes and
plasma cells (arrows) (H&E 40x) (e). The immunoﬂuorescence staining for C3 and C1q is shown in (f) and (g), respectively.
antigens. He was treated with oral ﬂuconazole. Because of
recurrent vomiting, an upper GI Endoscopy was performed
and revealed candida esophagitis (Figures 2(a) and 2(b)).
T h ep r e s e n c eo fd i ﬀuse cerebellar atrophy was noted on
followup MRI. Developmentally, the patient had global
delays. He sat at 1 year and stood with support at 2 years.
Bayley Scales of Infant Development when the patient was
2.5 years old revealed a mental age of 11 months and
a motor age of 6 months. Review of the family history
was negative for recognized genetic conditions, congenital
anomalies, and mental retardation. The patient is followed
in ophthalmology for esotropia and horizontal nystagmus.
His weight and height at the age of 8 years were less than
the 3rd centile, and his head circumference was 51cm, on
the 25th centile. He was subtly dysmorphic with a mask-
like facies, high forehead, epicanthal folds, thin upper lip,
and smooth philtrum, large mouth, and crowded teeth.
On CNS exam, he was noted to have increased tone, deep
tendon reﬂexes at 3/4, and downward ﬂexed feet. He had
sometimes abnormal involuntary and purposeless athetoid-
like movement of the upper extremities. Since the age of
8 years, the renal function has been noticed to gradually
decline with the urea rising from 4.8 to 35.2mmol/L, and
creatinineclimbingfrom67toashighasof1223µmol/L.The
renal ultrasonography showed small kidneys consistent with
chronic renal failure. The patient did not have evidence of
absorptive hypercalciuria.
3.MaterialsandMethods
3.1.CytogeneticsandFISHAnalysis. Cytogeneticanalysiswas
performedfromphytohemagglutininstimulatedlymphocyte
cultures by routine laboratory protocol. For microscopic4 Clinical and Developmental Immunology
analysis,metaphasechromosomeswerestainedwithtrypsin-
Giemsa technique, and 20 cells were analyzed and two to ﬁve
metaphases were karyotyped. Chromosome 4ToTelVysion
multicolor subtelomere DNA probes mixture; 4PTEL02
labelled with spectrum green and AFMA224XH1 (4Q
subtelomere) labelled with spectrum orange was used to
hybridize the p and q telomeres of chromosome 4 pair.
Pre- and posthybridization procedure was performed as per
manufacturer’s recommendation (Abbot-Vysis Inc., Catalog
no. 33-270000). At least 5–10metaphases were analyzed if
possible at 100x magniﬁcation objective under oil immer-
sion.
3.2. Array CGH Experiments and Data Analysis. We used the
Human Genome CGH Microarray Kit 244A (Agilent Tech-
nologies, Santa Clara, CA, USA) according to the manufac-
turer’s instructions with minor modiﬁcations. The Bioprime
Labeling Kit (Invitrogen Inc., Carlsbad, CA, USA) was used
to label all of digested patient’s DNA and reference DNA
separately with Cy5-dUTP and Cy3-dUTP (PerkinElmer,
Waltham, MA, USA), respectively. Labelled patient DNA
and reference DNA were mixed, puriﬁed, and prepared
for hybridization. After 38hrs of hybridization, repeated
wash cycles were performed according to the manufacturer’s
instructions. The images and data generated by the feature
extraction tool were loaded into CGH Analytics 3.4.40
software (Agilent Technologies) to allow visualization of the
data.
3.3. AIRE Gene Sequencing. Genomic DNA was isolated
by phenol/chloroform extraction. The 14 AIRE exons were
PCR-ampliﬁed(withorwithout7.5%ofDMSO),sequenced,
and analyzed on an ABI Prism 3700 apparatus (BigDye Ter-
minator sequencing kit, Applied Biosystems). The primers
used for PCR and sequencing are provided in Table 1.
3.4. Renal Histology and Immunoﬂuorescence. Fresh core
renal biopsy was examined under dissecting microscope
for the presence of cortex with glomeruli. Once cortex
was identiﬁed, a small (1mm) fragment was frozen for
immunoﬂuorescence. The remaining tissue was ﬁxed in
10% formalin for routine histology. Sections (2-3µm) were
prepared and stained with H&E (hematoxylin and eosin
stain), PAS (Periodic acid-Schiﬀ), Jones’, Masson trichrome,
andCongoredstains.Primaryantibodiesdirectlyconjugated
to ﬂuorescein isothiocyanate were utilized. No secondary
antibodies were used.
4. Results
4.1. Hormonal and Autoantibodies Assays. During followup,
the patient was investigated for associated polyendocrinopa-
thy and found to have hypoparathyroidism and adrenal
insuﬃciency with markedly low parathyroid hormone
(PTH) despite impaired renal function. The PTH was at 3-
4 (15–65ng/L), the adrenocorticotropic hormone (ACTH)
was high at 75–129 (5–60ng/L), and the free T4 was
slightly elevated at 24-25 (12–22pmol/L) while the TSH
Table 1: AIRE PCR and sequencing primers.
Primers Sequences (5 –3 )T m
1 Forward cgtggtcgcgggggtataaca 63◦C
1 Reverse tatccctggctcacagggcct
2 Forward ccccagccccaccctcaacac 65◦C
2 Reverse ccctttgcctcttaggatcca
3 Forward agctggactggaaccggagtg 60◦C
3 Reverse aaatgagacccgcccgcctac
4 Forward tgaagtaggcgggcgggtctc 65◦C
4 Reverse gacacaccaggccagcacgtc
5 Forward cacttgggtgcacacacgaac 60◦C
5 Reverse ttgcagaaggtcccccgacag
6/7 Forward tccccggccccagactcgac 65◦C
6/7 Reverse tcccagtggatccttgacctc
8 Forward aggaagggttcatgtggttgg 65◦C
8 Reverse cagcctgggatgagcttggac
9 Forward ccgttcctccttgccgtctc 55◦C
9 Reverse gccgttatcaatgctcatag
10 Forward agggtcccagcagtcactg 65◦C
10 Reverse ccctgtgcctcccggagcc
11 Forward agagaggtgcgggcgccagg 65◦C
11 Reverse tccccgccgaccacgctcac
12 Forward ccccacaccccataccccgga 65◦C
12 Reverse caggactctcaggctcatgc
13 Forward tggccctggtggtgcttgtc 65◦C
13 Reverse agcagtgggggccggcagtc
14 Forward tttgatggaatacggtgaag 60◦C
14 Reverse gcagatggtggtggcaatgg
was normal. In addition, the blood glucose and hemoglobin
A1c were normal. The antinuclear antibody (ANA) screen
and quantitative ANA were negative. A host of autoanti-
bodies including antiplatelet, anti HLA class I, antithyroid
Peroxidase, antithyroglobulin, liver and kidney microsomal
antiglomerular basement membrane, antimitochondrial,
and intrinsic factor autoantibodies were all normal. The
antismooth muscle autoantibodies were weakly positive. The
antiproximal tubular autoantibody testing was not available.
4.2. Renal Biopsy. The renal biopsy (Figures 2(c), 2(d),
and 2(e)) showed chronic tubular interstitial nephritis with
advanced ﬁbrosis. The immunoﬂuorescence demonstrated
mesangial deposition of C3 (3+), C1q (2+) (Figures 2(f) and
2(g)), and IgM (1+) (ﬁgure not shown) in the glomerulus
examined. The remaining immunoglobulins were negative
in the glomerular basement membrane, mesangium, and
extraglomerular structures.
4.3. Cytogenetic Analysis and FISH. The chromosomal study
revealed 46,XY,del(4)(q33) (Figure 3(a)). Parental chro-
mosomes were normal. Fluorescence in situ hybridization
(FISH) analysis using the 4P/4Q subtelomere DNA probe
conﬁrmed the presence of deletion 4q33 (Figure 3(b)).Clinical and Developmental Immunology 5
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Figure 3: Trypsin-Giemsa karyotype 46,XY,del(4)(q33) from peripheral blood cells in the patient, the arrow indicates the abnormal
chromosome 4 (a). Metaphase FISH image (b) from peripheral blood hybridized with Vysis 4p/4q subtelomere probes. The small arrow
shows the deletion of the 4qsubtel region (red) on the abnormal 4q33 deletion chromosome. The 4psubtel region shows the normal green
signals for both chromosomes 4. ish del(4)(q33)(4psubtel+; 4qsubtel−). The array CGH (c) depicting the terminal deletion on long arm of
chromosome 4 and its breakpoints. The deletion starts at 177,732,852 and ends at 191,279,059bp on Chr4 and is nearly 13.5Mb. There are
72 genes in the region based on NCBI Build 35.1 for Homosapiens.
4.4.ArrayCGH. ThearrayCGH(Figure3(c))showedalarge
deletionthatstartsat177,732,852andendsat191,279,059bp
on chromosome 4 and reﬁned the terminal deletion to be
starting at 4q34.3. The size of the deletion is nearly 13.5Mb
and has 90genes in the region based on NCBI Build 37.1 for
Homosapiens (supplementary table available online at doi:
10.1155/2010/586342).
4.5. AIRE Gene Sequencing. A c.845 846insC mutation
(p.Leu283SerfsX6) in exon 7 was found in the AIRE gene.
5. Discussion
APECED is a monogenic disease with autosomal recessive
inheritance characterized by multiple organ-speciﬁc autoim-
munity. The AIRE gene encompasses 13kb of genomic
DNA and includes 14 exons. It encodes a 545-amin-acid
transcription regulator of 57.5kDa. To date, more than
50 mutations have been identiﬁed in the coding region
[5, 22]. Pathogenic mutations within the AIRE gene trigger
an autoimmune destructive process in the target organs
by disturbing the immunological tolerance of the patients6 Clinical and Developmental Immunology
[23]. Our patient has interesting co-occurrence of AIRE
mutation causing APECED and the 4q terminal deletion
syndrome. A single patient report of renal failure was
reported in APECED in whom the renal biopsy revealed
tubulointerstitial nephritis with severe glomerular sclerosis,
but no renal immunoﬂuorescence result was mentioned.
Interestingly,multipleacuterejectionepisodesoccurredafter
renal transplant, and chronic rejection resulted in lost graft
that required retransplantation. The patient had a large
homozygous deletion (g.424 2157del1734) in AIRE gene.
Antiproximal tubular autoantibodies were detected in the
patient,andnootheretiologyofchronicinterstitialnephritis
was found, suggesting that the autoimmune mechanism was
important in the development of the interstitial nephritis
[8]. Tubulointerstitial nephritis was reported in 9% of the
FinnishAPECEDpatients,thelargestinternationalseries[7].
The renal biopsy in our case conﬁrms the same ﬁndings
of the tubulointerstitial involvement reported by Ulinski et
al. [8]. In our patient, however, the presence of C1q and
C3 strong mesangial deposition in the glomerulus examined
supports the evidence of autoimmune nephritis as the cause
of the renal failure. The homozygous base pair insertion of
cytosine at position 845 in our patient leads to a frame shift
and a stop codon at amino acid 288 of the AIRE protein.
It was previously reported only in one patient from Saudi
Arabia who has APECED without renal involvement [24]. It
has been hypothesized that renal autoantibodies could play a
roleintheinitialdevelopmentofchronicinterstitialnephritis
[8].
InAPECED,autoantibodiesarewellknowntobedirected
against various tissues (e.g., adrenal glands, liver, gonads,
and thyroid). On the cellular level, several autoantibodies are
directed against the cytochrome P450 enzyme (CYP) system
like17ahydroxylase(CYPC17),21-hydroxylase(CYP21)but
may target other antigens such as tryptophan hydroxylase
(TPH), tyrosine hydroxylase, interferons, and interleukin 17
and 22 cytokines, among others [4, 25–28]. Furthermore,
SOX9 and SOX10 transcription factors are vitiligo autoanti-
gens in APECED [29]. Association between the speciﬁc
autoantibodies and the disease process in APECED has
been established in Addison’s disease, hypoparathyroidism,
hypogonadism, diabetes mellitus, vitiligo autoimmune hep-
atitis, intestinal dysfunction, pernicious anemia, alopecia,
and autoimmune thyroid disease [4, 9, 30].
Our patient has the craniofacial features of 4q deletion
syndrome, as well as the profound psychomotor retardation
and poor growth. To the best of our knowledge, renal
anomalies have not been reported in 4q33 terminal deletion
cases. The only patient reported by Strehle and Bantock [15]
to have renal failure and 4q- syndrome had an interstitial
deletion 4q32q35. The patient underwent an emergency
cardiac surgery and developed kidney failure in the neonatal
period (personal communication). The area deleted in our
patient harbors a large number of genes, many of which are
of unknown function or have not been linked to a speciﬁc
phenotype. A gene of interest in the region deleted is the
toll-like receptor 3 gene (TLR3) at 4q35. Toll-like receptors
(TLRs) play an important role as a critical link between
the innate and adaptive immunity, and a disregulated TLR
signaling may be associated with autoimmune diseases [31].
T h er o l eo fh a p l o i n s u ﬃciency of TLR3 remains to be
elucidated. A dominant-negative TLR3 allele in otherwise
healthy children with herpes simplex virus 1 encephalitis
was reported. Mutations in TLR3 impair TLR3 responses
and confer a predisposition to herpes simplex encephalitis
[32].
The primary cause of the development of autoimmune
interstitial nephritis is quite intriguing in our patient
including the AIRE mutation, the 4q deletion, and possibly
some unknown genetic factor due to consanguinity. AIRE
gene defect may be favored as signiﬁcantly contributing to
the autoimmune nephropathy based on the following. (i)
T h ea u t o i m m u n en a t u r eo ft h er e n a li n v o l v e m e n ti no u r
patient based on renal biopsy immunoﬂuorescence. (ii) The
pathogenesis in APECED is based on autoimmunity, with
well-described multiorgan autoimmune dysfunction. (iii) A
previous case with renal failure and APECED and positive
antiproximal tubular autoantibodies. (iv) Lack of reported
cases with 4q terminal deletion syndrome and renal failure
due to tubulointerstitial nephritis. Nevertheless, this also
might be the ﬁrst case of autoimmune interstitial nephritis
because of terminal 4q deletion since the number of all
reported cases is small, and some form of renal involvement
in terminal 4q deletion was previously reported. In addition,
it is diﬃcult to know whether the deletion of TLR3 or
some other 4q genes had any contributory eﬀect on the
development of autoimmune nephropathy in this patient.
Finally, there is sometimes a tendency in chromosomal
deletions to attribute unusual ﬁndings to the deleted area.
This paper, however, provides a great example of coexistence
of two genetic mechanisms in the same patient resulting into
two phenotypes that can underlie atypical presentations of
primary immunodeﬁciency.
6. Conclusions
We present an interesting patient with APECED and 4q
deletion with autoimmune nephritis. Based on the fact
that autoimmunity is a basic pathogenesis mechanism in
APECED, our report presents more evidence of autoimmune
nephropathy in APECED. The diagnostic approach to this
case also depicts two unrelated genetic hits causing two
diﬀerent phenotypes in the same patient.
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